Central lung gene expression associates with myofibroblast features in idiopathic pulmonary fibrosis

Rationale Contribution of central lung tissues to pathogenesis of idiopathic pulmonary fibrosis (IPF) remains unknown. Objective To ascertain the relationship between cell types of IPF-central and IPF-peripheral lung explants using RNA sequencing (RNA-seq) transcriptome. Methods Biopsies of paired IPF-central and IPF-peripheral along with non-IPF lungs were selected by reviewing H&E data. Criteria for differentially expressed genes (DEG) were set at false discovery rate <5% and fold change >2. Computational cell composition deconvolution was performed. Signature scores were computed for each cell type. Findings Comparison of central IPF versus non-IPF identified 1723 DEG (1522 upregulated and 201 downregulated). Sixty-two per cent (938/1522) of the mutually upregulated genes in central IPF genes were also upregulated in peripheral IPF versus non-IPF. Moreover, 85 IPF central-associated genes (CAG) were upregulated in central IPF versus both peripheral IPF and central non-IPF. IPF single-cell RNA-seq analysis revealed the highest CAG signature score in myofibroblasts and significantly correlated with a previously published activated fibroblasts signature (r=0.88, p=1.6×10−4). CAG signature scores were significantly higher in IPF than in non-IPF myofibroblasts (p=0.013). Network analysis of central-IPF genes identified a module significantly correlated with the deconvoluted proportion of myofibroblasts in central IPF and anti-correlated with inflammation foci trait in peripheral IPF. The module genes were over-represented in idiopathic pulmonary fibrosis signalling pathways. Interpretation Gene expression in central IPF lung regions demonstrates active myofibroblast features that contributes to disease progression. Further elucidation of pathological transcriptomic state of cells in the central regions of the IPF lung that are relatively spared from morphological rearrangements may provide insights into molecular changes in the IPF progression.

[1]  Xiaochen Bo,et al.  clusterProfiler 4.0: A universal enrichment tool for interpreting omics data , 2021, Innovation.

[2]  C. Hung.  Origin of Myofibroblasts in Lung Fibrosis , 2020, Current Tissue Microenvironment Reports.

[3]  K. Clauser,et al.  MatrisomeDB: the ECM-protein knowledge database , 2019, Nucleic Acids Res..

[4]  Ziv Bar-Joseph,et al.  Transcriptional regulatory model of fibrosis progression in the human lung. , 2019, JCI insight.

[5]  Naftali Kaminski,et al.  Single Cell RNA-seq reveals ectopic and aberrant lung resident cell populations in Idiopathic Pulmonary Fibrosis , 2019, bioRxiv.

[6]  Jonathan A. Kropski,et al.  Single-cell RNA-sequencing reveals profibrotic roles of distinct epithelial and mesenchymal lineages in pulmonary fibrosis , 2019, bioRxiv.

[7]  M. Ni,et al.  Defining the Activated Fibroblast Population in Lung Fibrosis Using Single Cell Sequencing. , 2019, American journal of respiratory cell and molecular biology.

[8]  A. Shilatifard,et al.  Single-Cell Transcriptomic Analysis of Human Lung Provides Insights into the Pathobiology of Pulmonary Fibrosis , 2019, American journal of respiratory and critical care medicine.

[9]  G. Raghu,et al.  Pamrevlumab, an anti-connective tissue growth factor therapy, for idiopathic pulmonary fibrosis (PRAISE): a phase 2, randomised, double-blind, placebo-controlled trial. , 2019, The Lancet. Respiratory medicine.

[10]  N. Inui,et al.  LTBP2 is secreted from lung myofibroblasts and is a potential biomarker for idiopathic pulmonary fibrosis , 2018, Clinical science.

[11]  Nancy R. Zhang,et al.  Bulk tissue cell type deconvolution with multi-subject single-cell expression reference , 2018, Nature Communications.

[12]  Song Zhang.  The role of transforming growth factor β in T helper 17 differentiation , 2018, Immunology.

[13]  Peter Chen,et al.  Single-Cell Deconvolution of Fibroblast Heterogeneity in Mouse Pulmonary Fibrosis , 2018, Cell reports.

[14]  J. Galvin,et al.  Transcriptomic evidence of immune activation in macroscopically normal-appearing and scarred lung tissues in idiopathic pulmonary fibrosis. , 2018, Cellular immunology.

[15]  L. Richeldi,et al.  Idiopathic pulmonary fibrosis: pathogenesis and management , 2018, Respiratory Research.

[16]  Ryan Miller,et al.  WikiPathways: a multifaceted pathway database bridging metabolomics to other omics research , 2017, Nucleic Acids Res..

[17]  T. Mustelin,et al.  Antifibrotic role of vascular endothelial growth factor in pulmonary fibrosis , 2017, JCI insight.

[18]  G. Stratakos,et al.  Gaining access to the periphery of the lung: Bronchoscopic and transthoracic approaches , 2017, Annals of thoracic medicine.

[19]  A. Burke,et al.  Microscopic organizing pneumonia and cellular non-specific interstitial pneumonia are widespread in macroscopically normal-appearing lung tissue in idiopathic pulmonary fibrosis. , 2016, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[20]  Ivana V. Yang,et al.  Integrated Genomics Reveals Convergent Transcriptomic Networks Underlying Chronic Obstructive Pulmonary Disease and Idiopathic Pulmonary Fibrosis. , 2016, American journal of respiratory and critical care medicine.

[21]  G. Gudmundsson,et al.  Basal cells of the human airways acquire mesenchymal traits in idiopathic pulmonary fibrosis and in culture , 2015, Laboratory Investigation.

[22]  S. Kunugi,et al.  Role of α1 and α2 chains of type IV collagen in early fibrotic lesions of idiopathic interstitial pneumonias and migration of lung fibroblasts , 2015, Laboratory Investigation.

[23]  A. Devaraj.  Imaging: how to recognise idiopathic pulmonary fibrosis , 2014, European Respiratory Review.

[24]  Alexis Battle,et al.  Transcriptome Analysis Reveals Differential Splicing Events in IPF Lung Tissue , 2014, PloS one.

[25]  E. Herzog,et al.  Regulation and Relevance of Myofibroblast Responses in Idiopathic Pulmonary Fibrosis , 2013, Current Pathobiology Reports.

[26]  K. Lipson,et al.  CTGF is a central mediator of tissue remodeling and fibrosis and its inhibition can reverse the process of fibrosis , 2012, Fibrogenesis & tissue repair.

[27]  R. Voswinckel,et al.  Bone marrow transplantation improves hepatic fibrosis in Abcb4−/− mice via Th1 response and matrix metalloproteinase activity , 2011, Gut.

[28]  Gary Evans,et al.  Exploratory Multivariate Analysis by Example Using R , 2011 .

[29]  Takeshi Johkoh,et al.  American Thoracic Society Documents An Official ATS / ERS / JRS / ALAT Statement : Idiopathic Pulmonary Fibrosis : Evidence-based Guidelines for Diagnosis and Management , 2011 .

[30]  W. Coward,et al.  The pathogenesis of idiopathic pulmonary fibrosis , 2010, Therapeutic advances in respiratory disease.

[31]  Mark D. Robinson,et al.  edgeR: a Bioconductor package for differential expression analysis of digital gene expression data , 2009, Bioinform..

[32]  Jin Woo Song,et al.  Gene expression profiles of acute exacerbations of idiopathic pulmonary fibrosis. , 2009, American journal of respiratory and critical care medicine.

[33]  Naftali Kaminski,et al.  Gene expression profiles distinguish idiopathic pulmonary fibrosis from hypersensitivity pneumonitis. , 2006, American journal of respiratory and critical care medicine.

[34]  T. Wynn.  Fibrotic disease and the T(H)1/T(H)2 paradigm. , 2004, Nature reviews. Immunology.

[35]  Jeffrey Bonadio,et al.  Developmental Expression of Latent Transforming Growth Factor β Binding Protein 2 and Its Requirement Early in Mouse Development , 2000, Molecular and Cellular Biology.

[36]  V. Petkov,et al.  A preliminary study of long-term treatment with interferon gamma-1b and low-dose prednisolone in patients with idiopathic pulmonary fibrosis. , 1999, The New England journal of medicine.

[37]  R. Timpl,et al.  Supramolecular assembly of basement membranes , 1996, BioEssays : news and reviews in molecular, cellular and developmental biology.

[38]  A. Sher,et al.  An IL-12-based vaccination method for preventing fibrosis induced by schistosome infection , 1995, Nature.

[39]  Y. Benjamini,et al.  Controlling the false discovery rate: a practical and powerful approach to multiple testing , 1995 .